Company intelligence / Profile preview

Seahorse Bioscience

Billerica, Massachusetts, USAagilent.com ↗

Ownership: Private
Employees: ~175
Development stage: Commercial

Overview

Seahorse Bioscience developed and commercialized the industry-standard XF Extracellular Flux Analyzer platform for real-time measurement of cellular bioenergetics. Their products are widely used in academic and pharmaceutical research to study mitochondrial function and metabolic pathways relevant to many diseases. The company was acquired by Agilent Technologies in 2016 for $235 million.

Modalities: DeviceConsumable labware products
Industry: Non-Drug Biotech

Partnerships

Collaborated with major pharmaceutical companies during product design phase

Beyond the preview

Go deeper on Seahorse Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seahorse Bioscience.

Explore the full profile